Company research
Loading SEC business and financials…
AI relationship research has not yet been verified for this company.
Listing data synced 2026-04-16.
Loading your outlook…
Loading…
Loading company activity...
Estimated market cap
Unavailable
A supported share count and cached closing price are required.
Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. We have assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
Excerpt from Item 1 — Business; filed 2026-02-26. May be shortened.
Source: SEC Company Facts. Checked 2026-09-30. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.
Showing a previously fetched snapshot. A recent refresh has not completed.
